Lannett hopes to initiate a pivotal trial of its insulin glargine biosimilar candidate, in anticipation of a launch in 2024.
Lannett, a Philadelphia-based company, has announced the submission of a new drug application for a clinical trial of a potential biosimilar insulin glargine (long acting) product that the company is developing with HEC Group.
“This [investigational new drug] application is a key milestone and brings us one step closer to bringing this critically important and more affordable biosimilar medicine to the large and growing number of patients living with diabetes,” Tim Crew, CEO of Lannett, said in a statement.
Crew said the trial would be pivotal (play a key role in the regulatory approval of the product) and would commence roughly in March 2022. The company hopes to be able to file a biologics license application to the FDA in 2023 and launch by 2024, it said.
The biosimilar product would reference Lantus, produced by Sanofi, and was demonstrated in a volunteer pilot study to have similar pharmacokinetic and pharmacodynamic qualities. The new trial would be conducted in South Africa and has received approval to commence from that country’s Health Products Regulatory Authority.
“The trial site has experience with clinical insulin trials and has been used by other innovator firms for their insulin clinical trials,” Lannett said.
In March 2021, when Lannett first announced intentions to conduct a pivotal trial of its insulin glargine candidate, there were no biosimilar insulins on the US market.
That changed in July 2021 when Semglee, a Biocon Biologics/Viatris product, received FDA approval as the first insulin glargine biosimilar and the first interchangeable biosimilar, meaning pharmacists could substitute it for more-expensive brand products without prescribing physician intervention.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
October 16th 2024The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.